

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
UPDATE ON mRNA TECHNOLOGY PLATFORM DEVELOPMENT

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company has noted recent market developments regarding mRNA technology. mRNA is one of the key technology platforms of the Company. The Company is currently engaged in the development of mRNA preventive vaccines and therapeutic biologics as well as the development of related delivery systems. In respect of therapeutic areas, the Company is advancing its research and development of mRNA vaccines for the treatment of indications including glioblastoma, rhabdomyosarcoma and cervical cancer together with the development of In Vivo CAR-related therapies. All of the foregoing are currently at an early stage.

Recently, CanSino (Shanghai) Biological Research Co., Ltd. (“**CanSino Shanghai**”), a subsidiary of the Company, has entered into a strategic cooperation framework agreement with deepGeneAI (Hangzhou) Biotechnology Co., Ltd. (“**deepGeneAI**”) for the joint development of personalized mRNA therapeutic cancer vaccines (the “**Strategic Cooperation Framework Agreement**”). The Strategic Cooperation Framework Agreement provides a framework for CanSino Shanghai and deepGeneAI to explore collaboration by leveraging their respective strengths in mRNA vaccine technologies and tumor neoantigen discovery and design.

The board of directors considers that the development of the Company’s mRNA technology platform and the entering into of the Strategic Cooperation Framework Agreement are in line with the Company’s long-term strategy and in the interests of the Company and its shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, August 26, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.